全体不活化とは何ですか？
Whole Inactivated 全体不活化 - Some vaccine candidates of key interest are whole inactivated viruses, adeno‐associated viruses, virus‐like particles, and lipid nanoparticles. [1] Objectives: To evaluate the efficacy and safety of mucosal sublingual immunotherapy based on whole inactivated bacteria (MV130) in preventing WA in children. [2] Moreover, the multi-clade VLP showed high productivity (128–256 HAU) both in the laboratory and on a large scale, making it cheaper than whole inactivated vaccines produced in eggs. [3] Here, we report enhanced local mucosal and systemic immune responses through oral administration of H9N2 influenza whole inactivated virus (H9N2 WIV) plus Bacillus subtilis spores. [4] The disease can be effectively prevented by whole inactivated virus vaccines. [5] Oxford-AstraZeneca), expressing the modified spike gene (although whole inactivated SARS-CoV-2/ subunit vaccines have also been used elsewhere). [6] The development of more effective, accessible and easy to administer COVID-19 vaccines next to the currently marketed mRNA, viral vector and whole inactivated virus vaccines, is essential to curtain the SARS-CoV-2 pandemic. [7] A 6-plex protein array presenting the whole inactivated virus and five nucleocapsid and spike-derived SARS-CoV-2 antigens was used to generate a serological snapshot of SARS-CoV-2 seroprevalence and seroconversion in Israel in the early months of the pandemic. [8] In this study, we developed two whole inactivated vaccines, rgHS314 and vac564, against the Y280 and Y439 lineages, respectively, and evaluated their immunogenicity and protective efficacy against homologous or heterologous viral challenge in mice. [9] Similarly to whole inactivated bacteria used as human vaccines, this response is believed to confer only short-term, serogroup-specific protection. [10] Vaccines based on whole inactivated virus (WIV) and protein-based platforms, as well as protein particle-based vaccines, are the most produced by LMIC vaccine manufacturing strategies. [11] This two‐component vaccine could be a platform strategy, wherein HBsAg could be linked to the part of the cellular receptor that any new intractable virus binds to, and is administered together with whole inactivated virus. [12] For vaccination, this decoy protein is to be administered together with whole inactivated virus. [13] Female hamsters also had significantly greater IgG antibodies against whole inactivated SARS-CoV-2 and mutant S-RBDs, as well as virus neutralizing antibodies in plasma. [14] The whole inactivated TBE vaccine is highly effective, as proven by high seroconversion rates and near eradication of the disease in countries where vaccination programs have been implemented. [15] Vaccinated mice showed T cell response upon restimulation with whole inactivated SARS-CoV-2 or peptide pool. [16] Currently used whole inactivated virus (WIV) vaccines can induce vaccine-associated enhanced respiratory disease (VAERD) in pigs when the vaccine strains mismatch with the infected viruses. [17] Most vaccines contain whole inactivated bacteria which results in decreased efficacy due to the limited ability of the vaccine to evoke a cellular mediated immune response that can eliminate the pathogen or infected cells. [18] A swine influenza A pandemic 2009 H1N1 (pH1N1) virus was used in a pig challenge model to investigate the efficacy of whole inactivated vaccines homologous or heterologous to the challenge virus as well as a commercial vaccine. [19] In this study, we used a swine pH1N1 challenge virus to investigate the efficacy of whole inactivated virus vaccines homologous or heterologous to the challenge virus as well as a commercial vaccine. [20] Summary The efficacy, safety, speed, scalability and cost‐effectiveness of producing hemagglutinin‐based virus‐like particle (VLP) vaccines in plants are well‐established for human influenza, but untested for the massive poultry influenza vaccine market that remains dominated by traditional egg‐grown oil‐emulsion whole inactivated virus vaccines. [21] Adjuvanted whole inactivated virus (WIV) influenza vaccines show promise as broadly protective influenza vaccine candidates. [22] s) plus whole inactivated porcine epidemic diarrhea virus (PEDV WIV), followed by booster oral immunization. [23] The current study studied the role of gut microbiota in cell- and antibody-mediated immune responses to vaccination with a whole inactivated avian influenza virus, subtype H9N2. [24] One group was vaccinated (booster after 28 days) with a whole inactivated viral strain and the second group with a live recombinant canarypox virus expressing the genes coding for the WNV preM/E viral proteins. [25] Here, we evaluate the potential of whole inactivated vaccines, based on chemical and physical methods, as well as new approaches to generate cross‐protective immune responses. [26] We observed that different types of influenza vaccines (whole inactivated virus (WIV), split, and peptide vaccines) were all able to stimulate CD4 and CD8 T cell responses but to different extents in line with their reported in vivo properties. [27] Oropharyngeal swabs and tracheal lavage were collected daily and every other day, respectively, to evaluate virus shedding (qPCR) and blood was drawn on days 1, 14, 21, 28, and 49 for antibody titers (PRNT50), and PBMC activation (IFNγ ELISPOT with whole inactivated virus). [28] Although intranasal administration of whole inactivated virus vaccine can induce efficient protective immunity, formalin and β-propiolactone are the currently used and harmful inactivating agents. [29] The approach should aid in future screening of the virus and assist in the development of immunogenic peptide constructs as alternative treatments to vaccination over the whole inactivated virus. [30]重要なワクチン候補のいくつかは、完全不活化ウイルス、アデノ随伴ウイルス、ウイルス様粒子、および脂質ナノ粒子です。 [1] 目的：小児のWA予防における全不活化細菌（MV130）に基づく粘膜舌下免疫療法の有効性と安全性を評価すること。 [2] さらに、マルチクレードVLPは、実験室と大規模の両方で高い生産性（128〜256 HAU）を示し、卵で製造された不活化ワクチン全体よりも安価でした。 [3] ここでは、H9N2インフルエンザ全不活化ウイルス（H9N2 WIV）と枯草菌の胞子の経口投与による局所粘膜および全身免疫応答の強化を報告します。 [4] この病気は、不活化ウイルスワクチン全体で効果的に予防することができます。 [5] Oxford-AstraZeneca）、改変されたスパイク遺伝子を発現します（ただし、不活化されたSARS-CoV-2 /サブユニットワクチン全体が他の場所でも使用されています）。 [6] 現在市販されているmRNA、ウイルスベクター、および完全不活化ウイルスワクチンの次に、より効果的でアクセスしやすく、投与が容易なCOVID-19ワクチンの開発は、SARS-CoV-2のパンデミックを食い止めるために不可欠です。 [7] 不活化ウイルス全体と5つのヌクレオカプシドおよびスパイク由来のSARS-CoV-2抗原を提示する6プレックスタンパク質アレイを使用して、パンデミックの初期のイスラエルにおけるSARS-CoV-2血清有病率および抗体陽転の血清学的スナップショットを生成しました。 [8] この研究では、Y280およびY439系統に対して、それぞれrgHS314およびvac564の2つの完全不活化ワクチンを開発し、マウスにおける同種または異種のウイルス攻撃に対する免疫原性および防御効果を評価しました。 [9] ヒトワクチンとして使用される不活化細菌全体と同様に、この反応は短期間の血清型特異的防御のみを与えると考えられています。 [10] 全不活化ウイルス（WIV）とタンパク質ベースのプラットフォームに基づくワクチン、およびタンパク質粒子ベースのワクチンは、LMICワクチン製造戦略によって最も多く生産されています。 [11] この2成分ワクチンは、HBsAgが細胞受容体の新しい難治性ウイルスが結合する部分に結合し、不活化ウイルス全体と一緒に投与されるプラットフォーム戦略である可能性があります。 [12] ワクチン接種の場合、このおとりタンパク質は、不活化ウイルス全体と一緒に投与されます。 [13] メスのハムスターはまた、不活化されたSARS-CoV-2および変異体S-RBD全体に対するIgG抗体、および血漿中のウイルス中和抗体が有意に多かった。 [14] ワクチン接種プログラムが実施されている国では、セロコンバージョン率が高く、病気がほぼ根絶されていることからもわかるように、不活化TBEワクチン全体が非常に効果的です。 [15] ワクチン接種されたマウスは、完全に不活化されたSARS-CoV-2またはペプチドプールで再刺激するとT細胞応答を示しました。 [16] 現在使用されている全不活化ウイルス（WIV）ワクチンは、ワクチン株が感染したウイルスと一致しない場合、ブタにワクチン関連の強化呼吸器疾患（VAERD）を誘発する可能性があります。 [17] ほとんどのワクチンには不活化細菌が含まれているため、病原体や感染細胞を排除できる細胞性免疫応答を誘発するワクチンの能力が限られているため、有効性が低下します。 [18] nan [19] nan [20] nan [21] nan [22] nan [23] nan [24] nan [25] nan [26] nan [27] nan [28] nan [29] nan [30]
whole inactivated viru 全不活化ウイルス
Here, we report enhanced local mucosal and systemic immune responses through oral administration of H9N2 influenza whole inactivated virus (H9N2 WIV) plus Bacillus subtilis spores. [1] The disease can be effectively prevented by whole inactivated virus vaccines. [2] The development of more effective, accessible and easy to administer COVID-19 vaccines next to the currently marketed mRNA, viral vector and whole inactivated virus vaccines, is essential to curtain the SARS-CoV-2 pandemic. [3] A 6-plex protein array presenting the whole inactivated virus and five nucleocapsid and spike-derived SARS-CoV-2 antigens was used to generate a serological snapshot of SARS-CoV-2 seroprevalence and seroconversion in Israel in the early months of the pandemic. [4] Vaccines based on whole inactivated virus (WIV) and protein-based platforms, as well as protein particle-based vaccines, are the most produced by LMIC vaccine manufacturing strategies. [5] This two‐component vaccine could be a platform strategy, wherein HBsAg could be linked to the part of the cellular receptor that any new intractable virus binds to, and is administered together with whole inactivated virus. [6] For vaccination, this decoy protein is to be administered together with whole inactivated virus. [7] Currently used whole inactivated virus (WIV) vaccines can induce vaccine-associated enhanced respiratory disease (VAERD) in pigs when the vaccine strains mismatch with the infected viruses. [8] In this study, we used a swine pH1N1 challenge virus to investigate the efficacy of whole inactivated virus vaccines homologous or heterologous to the challenge virus as well as a commercial vaccine. [9] Summary The efficacy, safety, speed, scalability and cost‐effectiveness of producing hemagglutinin‐based virus‐like particle (VLP) vaccines in plants are well‐established for human influenza, but untested for the massive poultry influenza vaccine market that remains dominated by traditional egg‐grown oil‐emulsion whole inactivated virus vaccines. [10] Adjuvanted whole inactivated virus (WIV) influenza vaccines show promise as broadly protective influenza vaccine candidates. [11] We observed that different types of influenza vaccines (whole inactivated virus (WIV), split, and peptide vaccines) were all able to stimulate CD4 and CD8 T cell responses but to different extents in line with their reported in vivo properties. [12] Oropharyngeal swabs and tracheal lavage were collected daily and every other day, respectively, to evaluate virus shedding (qPCR) and blood was drawn on days 1, 14, 21, 28, and 49 for antibody titers (PRNT50), and PBMC activation (IFNγ ELISPOT with whole inactivated virus). [13] Although intranasal administration of whole inactivated virus vaccine can induce efficient protective immunity, formalin and β-propiolactone are the currently used and harmful inactivating agents. [14] The approach should aid in future screening of the virus and assist in the development of immunogenic peptide constructs as alternative treatments to vaccination over the whole inactivated virus. [15]ここでは、H9N2インフルエンザ全不活化ウイルス（H9N2 WIV）と枯草菌の胞子の経口投与による局所粘膜および全身免疫応答の強化を報告します。 [1] この病気は、不活化ウイルスワクチン全体で効果的に予防することができます。 [2] 現在市販されているmRNA、ウイルスベクター、および完全不活化ウイルスワクチンの次に、より効果的でアクセスしやすく、投与が容易なCOVID-19ワクチンの開発は、SARS-CoV-2のパンデミックを食い止めるために不可欠です。 [3] 不活化ウイルス全体と5つのヌクレオカプシドおよびスパイク由来のSARS-CoV-2抗原を提示する6プレックスタンパク質アレイを使用して、パンデミックの初期のイスラエルにおけるSARS-CoV-2血清有病率および抗体陽転の血清学的スナップショットを生成しました。 [4] 全不活化ウイルス（WIV）とタンパク質ベースのプラットフォームに基づくワクチン、およびタンパク質粒子ベースのワクチンは、LMICワクチン製造戦略によって最も多く生産されています。 [5] この2成分ワクチンは、HBsAgが細胞受容体の新しい難治性ウイルスが結合する部分に結合し、不活化ウイルス全体と一緒に投与されるプラットフォーム戦略である可能性があります。 [6] ワクチン接種の場合、このおとりタンパク質は、不活化ウイルス全体と一緒に投与されます。 [7] 現在使用されている全不活化ウイルス（WIV）ワクチンは、ワクチン株が感染したウイルスと一致しない場合、ブタにワクチン関連の強化呼吸器疾患（VAERD）を誘発する可能性があります。 [8] nan [9] nan [10] nan [11] nan [12] nan [13] nan [14] nan [15]
whole inactivated vaccine 全不活化ワクチン
Moreover, the multi-clade VLP showed high productivity (128–256 HAU) both in the laboratory and on a large scale, making it cheaper than whole inactivated vaccines produced in eggs. [1] In this study, we developed two whole inactivated vaccines, rgHS314 and vac564, against the Y280 and Y439 lineages, respectively, and evaluated their immunogenicity and protective efficacy against homologous or heterologous viral challenge in mice. [2] A swine influenza A pandemic 2009 H1N1 (pH1N1) virus was used in a pig challenge model to investigate the efficacy of whole inactivated vaccines homologous or heterologous to the challenge virus as well as a commercial vaccine. [3] Here, we evaluate the potential of whole inactivated vaccines, based on chemical and physical methods, as well as new approaches to generate cross‐protective immune responses. [4]さらに、マルチクレードVLPは、実験室と大規模の両方で高い生産性（128〜256 HAU）を示し、卵で製造された不活化ワクチン全体よりも安価でした。 [1] この研究では、Y280およびY439系統に対して、それぞれrgHS314およびvac564の2つの完全不活化ワクチンを開発し、マウスにおける同種または異種のウイルス攻撃に対する免疫原性および防御効果を評価しました。 [2] nan [3] nan [4]
whole inactivated bacterium 全不活化菌
Objectives: To evaluate the efficacy and safety of mucosal sublingual immunotherapy based on whole inactivated bacteria (MV130) in preventing WA in children. [1] Similarly to whole inactivated bacteria used as human vaccines, this response is believed to confer only short-term, serogroup-specific protection. [2] Most vaccines contain whole inactivated bacteria which results in decreased efficacy due to the limited ability of the vaccine to evoke a cellular mediated immune response that can eliminate the pathogen or infected cells. [3]目的：小児のWA予防における全不活化細菌（MV130）に基づく粘膜舌下免疫療法の有効性と安全性を評価すること。 [1] ヒトワクチンとして使用される不活化細菌全体と同様に、この反応は短期間の血清型特異的防御のみを与えると考えられています。 [2] ほとんどのワクチンには不活化細菌が含まれているため、病原体や感染細胞を排除できる細胞性免疫応答を誘発するワクチンの能力が限られているため、有効性が低下します。 [3]
whole inactivated sar 全不活化サル
Oxford-AstraZeneca), expressing the modified spike gene (although whole inactivated SARS-CoV-2/ subunit vaccines have also been used elsewhere). [1] Female hamsters also had significantly greater IgG antibodies against whole inactivated SARS-CoV-2 and mutant S-RBDs, as well as virus neutralizing antibodies in plasma. [2] Vaccinated mice showed T cell response upon restimulation with whole inactivated SARS-CoV-2 or peptide pool. [3]Oxford-AstraZeneca）、改変されたスパイク遺伝子を発現します（ただし、不活化されたSARS-CoV-2 /サブユニットワクチン全体が他の場所でも使用されています）。 [1] メスのハムスターはまた、不活化されたSARS-CoV-2および変異体S-RBD全体に対するIgG抗体、および血漿中のウイルス中和抗体が有意に多かった。 [2] ワクチン接種されたマウスは、完全に不活化されたSARS-CoV-2またはペプチドプールで再刺激するとT細胞応答を示しました。 [3]